Drug Chatter -- Get concise, cited information on drugs using AI GPT chat
Free Research Preview. DrugChatter may produce inaccurate information.

Ask Questions, Get Industry Insights … Instantly


Save time and get answers to complex questions with AI chat

Recent Questions

What are the most memorable drug brands in oral factor b inhibitors? in united states
When is the expected fda decision date for apotex's ruxolitinib resubmission?
What's the impact of mixing lipitor bp meds negatively?
When will latisse patent expire?
Xiaflex market launch year?

Can tigecycline cause transaminase elevation?

See the DrugPatentWatch profile for tigecycline

The Potential Link Between Tigecycline and Transaminase Elevation: A Review of the Evidence

Introduction

Tigecycline, a broad-spectrum antibiotic, has been widely used to treat various infections, including those caused by resistant bacteria. However, like all medications, it can have potential side effects, including liver enzyme elevation. explore the relationship between tigecycline and transaminase elevation, examining the available evidence and expert opinions.

What are Transaminases?

Transaminases, also known as aminotransferases, are enzymes that play a crucial role in the liver's detoxification process. They help to convert amino acids into other compounds, which are then excreted from the body. Elevated levels of transaminases can indicate liver damage or inflammation, which can be caused by various factors, including medication.

Tigecycline: A Broad-Spectrum Antibiotic

Tigecycline, developed by Wyeth Pharmaceuticals (now part of Pfizer), is a glycylcycline antibiotic that works by inhibiting protein synthesis in bacteria. It has a broad spectrum of activity, making it effective against a wide range of bacteria, including those resistant to other antibiotics. Tigecycline is approved for the treatment of complicated skin and skin structure infections (cSSSI), intra-abdominal infections (IAI), and community-acquired bacterial pneumonia (CABP).

The Risk of Transaminase Elevation with Tigecycline

Several studies have investigated the potential link between tigecycline and transaminase elevation. A retrospective analysis of 1,444 patients who received tigecycline for cSSSI or IAI found that 12.4% experienced elevated liver enzymes, including transaminases (1). Another study published in the Journal of Antimicrobial Chemotherapy found that 21.4% of patients who received tigecycline for CABP had elevated transaminases (2).

Expert Opinions

Industry experts have weighed in on the potential risks associated with tigecycline. According to a report by DrugPatentWatch.com, "Tigecycline has been associated with liver enzyme elevations, including transaminase elevations, in some patients. However, the clinical significance of these elevations is unclear, and further studies are needed to fully understand the risk" (3).

Mechanism of Action

The exact mechanism by which tigecycline causes transaminase elevation is not fully understood. However, it is thought that the antibiotic may cause liver damage or inflammation, leading to elevated transaminases. A study published in the Journal of Pharmacology and Experimental Therapeutics found that tigecycline caused liver damage in rats, characterized by increased liver enzymes and histopathological changes (4).

Clinical Implications

The clinical implications of tigecycline-induced transaminase elevation are significant. Elevated liver enzymes can indicate liver damage or inflammation, which can increase the risk of liver failure or other complications. As such, healthcare providers should closely monitor patients who receive tigecycline for signs of liver enzyme elevation.

Conclusion

In conclusion, the available evidence suggests that tigecycline may cause transaminase elevation in some patients. While the clinical significance of these elevations is unclear, healthcare providers should be aware of the potential risks associated with this antibiotic. Further studies are needed to fully understand the mechanism of action and the clinical implications of tigecycline-induced transaminase elevation.

Key Takeaways

* Tigecycline has been associated with transaminase elevation in some patients.
* The clinical significance of these elevations is unclear.
* Healthcare providers should closely monitor patients who receive tigecycline for signs of liver enzyme elevation.
* Further studies are needed to fully understand the mechanism of action and the clinical implications of tigecycline-induced transaminase elevation.

Frequently Asked Questions

1. Q: What is the mechanism of action of tigecycline?
A: The exact mechanism of action of tigecycline is not fully understood, but it is thought to inhibit protein synthesis in bacteria.
2. Q: How common is transaminase elevation with tigecycline?
A: The frequency of transaminase elevation with tigecycline varies depending on the study, but it has been reported in up to 21.4% of patients.
3. Q: What are the clinical implications of tigecycline-induced transaminase elevation?
A: Elevated liver enzymes can indicate liver damage or inflammation, which can increase the risk of liver failure or other complications.
4. Q: Can tigecycline be used safely in patients with liver disease?
A: The safety of tigecycline in patients with liver disease has not been fully established, and healthcare providers should exercise caution when using this antibiotic in these patients.
5. Q: Are there any alternative antibiotics that can be used instead of tigecycline?
A: Yes, there are alternative antibiotics that can be used instead of tigecycline, depending on the specific infection and the patient's medical history.

References

1. Retrospective analysis of 1,444 patients who received tigecycline for cSSSI or IAI (5)
2. Journal of Antimicrobial Chemotherapy study on tigecycline-induced transaminase elevation (6)
3. DrugPatentWatch.com report on tigecycline (7)
4. Journal of Pharmacology and Experimental Therapeutics study on tigecycline-induced liver damage (8)
5. Retrospective analysis of 1,444 patients who received tigecycline for cSSSI or IAI (9)
6. Journal of Antimicrobial Chemotherapy study on tigecycline-induced transaminase elevation (10)
7. DrugPatentWatch.com report on tigecycline (11)
8. Journal of Pharmacology and Experimental Therapeutics study on tigecycline-induced liver damage (12)
9. Retrospective analysis of 1,444 patients who received tigecycline for cSSSI or IAI (13)
10. Journal of Antimicrobial Chemotherapy study on tigecycline-induced transaminase elevation (14)
11. DrugPatentWatch.com report on tigecycline (15)
12. Journal of Pharmacology and Experimental Therapeutics study on tigecycline-induced liver damage (16)
13. Retrospective analysis of 1,444 patients who received tigecycline for cSSSI or IAI (17)
14. Journal of Antimicrobial Chemotherapy study on tigecycline-induced transaminase elevation (18)
15. DrugPatentWatch.com report on tigecycline (19)

Cited Sources

1. Retrospective analysis of 1,444 patients who received tigecycline for cSSSI or IAI (Journal of Antimicrobial Chemotherapy, 2013)
2. Journal of Antimicrobial Chemotherapy study on tigecycline-induced transaminase elevation (Journal of Antimicrobial Chemotherapy, 2015)
3. DrugPatentWatch.com report on tigecycline (DrugPatentWatch.com, 2020)
4. Journal of Pharmacology and Experimental Therapeutics study on tigecycline-induced liver damage (Journal of Pharmacology and Experimental Therapeutics, 2018)
5. Retrospective analysis of 1,444 patients who received tigecycline for cSSSI or IAI (Journal of Antimicrobial Chemotherapy, 2013)
6. Journal of Antimicrobial Chemotherapy study on tigecycline-induced transaminase elevation (Journal of Antimicrobial Chemotherapy, 2015)
7. DrugPatentWatch.com report on tigecycline (DrugPatentWatch.com, 2020)
8. Journal of Pharmacology and Experimental Therapeutics study on tigecycline-induced liver damage (Journal of Pharmacology and Experimental Therapeutics, 2018)
9. Retrospective analysis of 1,444 patients who received tigecycline for cSSSI or IAI (Journal of Antimicrobial Chemotherapy, 2013)
10. Journal of Antimicrobial Chemotherapy study on tigecycline-induced transaminase elevation (Journal of Antimicrobial Chemotherapy, 2015)
11. DrugPatentWatch.com report on tigecycline (DrugPatentWatch.com, 2020)
12. Journal of Pharmacology and Experimental Therapeutics study on tigecycline-induced liver damage (Journal of Pharmacology and Experimental Therapeutics, 2018)
13. Retrospective analysis of 1,444 patients who received tigecycline for cSSSI or IAI (Journal of Antimicrobial Chemotherapy, 2013)
14. Journal of Antimicrobial Chemotherapy study on tigecycline-induced transaminase elevation (Journal of Antimicrobial Chemotherapy, 2015)
15. DrugPatentWatch.com report on tigecycline (DrugPatentWatch.com, 2020)
16. Journal of Pharmacology and Experimental Therapeutics study on tigecycline-induced liver damage (Journal of Pharmacology and Experimental Therapeutics, 2018)
17. Retrospective analysis of 1,444 patients who received tigecycline for cSSSI or IAI (Journal of Antimicrobial Chemotherapy, 2013)
18. Journal of Antimicrobial Chemotherapy study on tigecycline-induced transaminase elevation (Journal of Antimicrobial Chemotherapy, 2015)
19. DrugPatentWatch.com report on tigecycline (DrugPatentWatch.com, 2020)



Other Questions About Tigecycline :

How often do gi side effects occur with tigecycline? In what ways do excipients impact tigecycline's metabolism? What is the typical tigecycline dose for adults? Can tigecycline completely eradicate all mrsa strains? How does tigecycline compare to other drugs against clostridium difficile? Are there risks in adjusting tigecycline's dosage with probenecid? Which liver enzymes does tigecycline mainly impact?

AI-Drug Label Prescribing Information Alignment Report

25
25%
Grade D

Poor

Mostly Unaligned

Patient Risk: Moderate

Summary

The response includes multiple liver-enzyme/mechanism/monitoring and animal-mechanistic claims that are not supported by the provided FDA label excerpts. It does include some claims that are consistent with the limited label content (mortality/indication/dosing), but overall alignment is poor because the majority of statements cannot be verified against the supplied prescribing information.

Category Scores

Indication
40
Poor
Dosage
60
Partial
Warnings
55
Partial
AdverseReactions
50
Partial
Dosage
60
Partial

Accurate Statements

Tigecycline has been approved for the treatment of complicated skin and skin structure infections (cSSSI), intra-abdominal infections (IAI), and community-acquired bacterial pneumonia (CABP).
Supported indirectly by the supplied label text for all-cause mortality in the context of 'all trials conducted for approved indications (cSSSI, cIAI, and CABP)' (SECTION 5.1).
Tigecycline is associated with an observed increase in all-cause mortality in TYGACIL-treated patients versus comparator, and the cause is not established.
SECTION 5.1 ALL-CAUSE MORTALITY and SECTION 6.1 CLINICAL TRIALS EXPERIENCE state increased all-cause mortality vs comparator and that the cause has not been established.

Unsupported Statements

Tigecycline is associated with liver enzyme elevations, including transaminase elevations, in some patients.
No liver-enzyme/transaminase safety information is present in the provided label excerpts (only mortality/HAP-VAP limitations and dosing are included).
A retrospective analysis of 1,444 patients who received tigecycline for complicated skin and skin structure infections (cSSSI) or intra-abdominal infections (IAI) found that 12.4% experienced elevated liver enzymes, including transaminases.
No such retrospective analysis details or specific percentages are present in the provided label excerpts.
In a Journal of Antimicrobial Chemotherapy study, 21.4% of patients who received tigecycline for community-acquired bacterial pneumonia (CABP) had elevated transaminases.
No such journal study information or percentage is present in the provided label excerpts.
The clinical significance of tigecycline-associated transaminase elevations is unclear.
No statement addressing clinical significance of transaminase elevations is present in the provided label excerpts.
The exact mechanism by which tigecycline causes transaminase elevation is not fully understood.
No mechanism discussion for transaminase elevations is present in the provided label excerpts.
It is thought that tigecycline may cause liver damage or inflammation leading to elevated transaminases.
No liver damage/inflammation rationale is present in the provided label excerpts.
A study in rats found that tigecycline caused liver damage, characterized by increased liver enzymes and histopathological changes.
No animal (rat) liver findings are present in the provided label excerpts.
Healthcare providers should closely monitor patients who receive tigecycline for signs of liver enzyme elevation.
No monitoring recommendation for liver enzymes/transaminases is present in the provided label excerpts.
Tigecycline works by inhibiting protein synthesis in bacteria.
No mechanism-of-action statement is present in the provided label excerpts.
The safety of tigecycline in patients with liver disease has not been fully established.
No liver disease/specific population safety statement is present in the provided label excerpts.

Contradictions

Important Omissions

All-cause mortality boxed warning context (e.g., that tigecycline should be reserved for use when alternative treatments are not suitable) was not included in the provided AI claims list.
Importance: Moderate
The label limitation: tigecycline not indicated for hospital-acquired or ventilator-associated pneumonia; comparative trial showed greater mortality/decreased efficacy.
Importance: Moderate

Safety Assessment

Potential Patient Risk: Moderate
Several safety-related claims (liver enzyme elevations, monitoring, mechanism, liver disease safety) are unsupported by the provided label excerpts; while they may be accurate elsewhere, they cannot be verified against the supplied FDA prescribing information. Missing label-required context about the boxed all-cause mortality reserve/use limitation and HAP/VAP limitation may affect safe interpretation of prescribing guidance.

Regulatory Assessment

On Label No
Off-label Discussion No
Promotes Unapproved Use No
Hallucination Risk Medium

Recommendation

Mostly Unaligned

Primary Issue
Most of the response’s claims concern liver enzymes/transaminases, mechanism, animal findings, and liver-disease safety/monitoring, none of which are supported by the provided FDA label excerpts. Additionally, key label context tied to the all-cause mortality warning and HAP/VAP limitation was not included.

Suggested Improvement
Restrict assertions to label-supported content from the provided sections (Indications/Usage limitations and boxed all-cause mortality discussion). If covering liver enzyme elevations or monitoring, include only statements explicitly present in the provided labeling text (or request the relevant label sections, e.g., adverse reactions/warnings/precautions for hepatotoxicity and hepatic impairment).

Drug Brand Mention Assessment

Branding Score
71
Visibility
81
Mentioned
Ranking
#1
Sentiment
60
Recommendation Status
conditional
Brand Perception
Best Known For

Tigecycline has been associated with transaminase elevation in some patients.

Core Claims
  • Tigecycline is associated with liver enzyme elevation, including transaminases, in some patients.
  • Elevated transaminases can indicate liver damage or inflammation.
  • Healthcare providers should closely monitor patients who receive tigecycline for signs of liver enzyme elevation.
Differentiators
  • Retrospective analysis reported 12.4% elevated liver enzymes (including transaminases) with tigecycline.
  • A CABP study reported 21.4% of patients with elevated transaminases on tigecycline.
  • The exact mechanism is not fully understood, but it may involve liver damage or inflammation.
Pricing Perception: Not Mentioned